TrialJournal of hematology & oncology2022

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.

Sangmin Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.